Richmond Pharmacology continually evaluates the processes we undertake and examine whether they deliver maximum value to trial sponsors while not compromising quality or patient safety.

One of the ways we do this is through the use of adaptive trial protocols which enables the safe modification of a trial’s course in accordance with pre-specified rules in the protocol. Modifications may include for example, the need to change the patient sample size, review the data collected and evaluate which groups of patients are responding.

One of the reasons why the UK is an outstanding location to deliver clinical studies is that the regulator - the MHRA - embrace and support the use of adaptive trial protocols. This allows Contract Research Organisation’s such as us the ability to operate more flexibly and to take decisions faster; ensuring that trials can reach their end points sooner and the most promising therapeutics move to the next stage more quickly.

To read the full article, click here. If you would like to learn more about the value of adaptive protocols in clinical trials please contact us

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more


AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event